We have launched 3 self-developed monoclonal antibody (mAb) biosimilars including the first Chinese biosimilar 汉利康® (rituximab), the first Chinese mAb biosimilar entering both China and the EU market 汉曲优® (trastuzumab) and 汉达远® (adalimumab), navigating at the forefront of Chinese biopharmaceutical industry.
Adopting “Combo+Global” differentiation strategy, we have versatile in-house combination therapy portfolio with a focus on Serplulimab (anti-PD-1 mAb) and clinical trials of 2 monotherapies and 8 combination therapies underway worldwide, to capture future immuno-oncology opportunities.
Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies.
We have 3 manufacturing facilities, namely Xuhui / Songjiang (First Plant) and Songjiang (Second Plant) Manufacturing Facility. Our commercial capacity totals 20,000L for now with an estimate of 80,000L in 3 years. Xuhui Manufacturing Facility is certificated by China and the EU Good Manufacturing Practice (GMP).
We have built an in-house commercial team focused on domestic market and established market presence in over 260 cities across 6 sales regions in China; we have also joined forces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide.
Henlius upholds the talent philosophy of “attracting people with visions, engaging people with rewards, cultivating people with challenges and assessing people with performance” and makes great efforts in attracting, empowering, retaining people and putting right people to right place.